1.
María-Victoria Mateos, Sara Bringhen, Paul G. Richardson, Juan Jose Lahuerta, Alessandra Larocca, Albert Oriol, Mario Boccadoro, Ramón García-Sanz, Francesco Di Raimondo, Dixie-Lee Esseltine, Helgi van de Velde, Avinash Desai, Anil Londhe, Jesús F. San Miguel, Antonio Palumbo. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. haematol [Internet]. 2014Jun.1 [cited 2024Feb.28];99(6):1114-22. Available from: https://haematologica.org/article/view/7054